Project Grant R01CA289307
Award Date
4/23/25
Completion Date
3/31/30
Dollars Obligated
$707K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $667,533 Project Grant to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on targeting lymphoma using a multimodal approach involving radiation therapy, CAR-T cell therapy, and gut microbiome modulation. The research builds upon the grantee's previous groundbreaking findings, which demonstrated that combining oral...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Trustees of the University of Pennsylvania to conduct research on using the FDA-approved drug Photofrin and other heme oxygenase-1 (HO-1) inducing agents as potential therapeutic options for malignant pleural mesothelioma (MPM), an aggressive form of cancer. The $227,906 award, effective from January 1, 2025 to December 31, 2026, aims to: 1) characterize the tumor control...
This $516,114 Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports a clinical trial to investigate the impact of immediate lymphatic reconstruction (ILR) surgery on preventing lymphedema in patients with inflammatory breast cancer (IBC). The key products and services to be delivered under this 5-year grant include: Determining the incidence of clinical lymphedema in IBC patients following ILR surgery Establishing a...
The Defense Health Agency awarded a $1,357,177 Project Grant titled "Promoting Self-Management in Head and Neck Cancer Survivors with Lymphedema and Fibrosis (PROMISE Trial)" to The Trustees of the University of Pennsylvania (Penn). This grant, provided under the CFDA Program 12.420 "Military Medical Research and Development", will fund research to compare the effects of in-person and telehealth lymphedema and fibrosis self-management programs versus usual care on symptom...
The National Cancer Institute (NCI) awarded a $200,000 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, awarded on September 15, 2023, supports research to develop novel therapeutic approaches to remediate radiotherapy-induced bone necrosis in oropharyngeal cancer patients, particularly among African-American populations who...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $275,837 to Northwestern University for a 5-year period beginning on August 1, 2024. The grant will support research to develop a new photothermal therapy (PTT) platform using gold nanoparticles and immune stimulants (CPGs) for the treatment of relapsed/refractory B-cell lymphomas. The research aims to characterize the anti-lymphoma immune mechanisms of the PTT/CPG platform,...
This $238,824 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research to optimize lung cancer treatment decisions and quality-adjusted life years through improved lymph node staging. The project, led by The General Hospital Corporation (Massachusetts General Hospital), aims to leverage an ongoing cohort study to evaluate the ability of two lymph node biopsy procedures, endobronchial ultrasound (EBUS) and mediastinoscopy, to detect...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $662,516 aims to investigate how fractionated radiation affects the tumor microenvironment to enhance drug delivery and improve the safety and efficacy of chemoradiotherapy for locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The key research objectives include: 1) Quantifying how local radiation reshapes the tumor microenvironment to influence...
The National Cancer Institute (NCI) awarded a $657,121 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant, effective from December 12, 2024 to November 30, 2029, aims to develop a novel dendritic cell therapy to treat leptomeningeal disease (LMD), a serious complication that occurs in 5% of advanced-stage breast cancer patients. The proposed therapy involves using polarized conventional...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) in the amount of $664,304 will fund a study to investigate the biological and social determinants of psychosocial outcomes among patients with advanced head and neck cancer receiving immunotherapy treatments. The key objectives of this 5-year study are to (1) understand the psychosocial sequelae (e.g., fatigue, depression) experienced by these patients, (2) identify the...